Drugs / JNS001
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01357993 | May 2011 → Mar 2013 | attention deficit-hyperactivity disorder | Janssen Pharmaceutical K.K. | Completed | No outcome recorded |
| Phase 3 | NCT01323192 | Mar 2011 → Apr 2012 | attention deficit-hyperactivity disorder | Janssen Pharmaceutical K.K. | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JNS001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01357993 ↗ |
| Route | Oral | “Participants will receive JNS001 (18 mg, 36 mg, 54 mg or 72 mg per day) orally once daily for 8 weeks.” NCT01323192 ↗ |